XML 38 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

During the year ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K for the purchase or sale of our securities, except as set forth below:

Name and Title

Type of Plan

Adoption Date

Duration or End Date

Aggregate Number of Securities to be Sold

Description of Trading Arrangement

Rachel Humphrey, M.D.
Director

Rule 10b5-1 trading arrangement

December 5, 2024

March 26, 2025 - February 27, 2026

259,454

Sales of shares intended to satisfy the affirmative defense of Rule 10b5–1(c)

Lara Sullivan, M.D.
President and Chief Executive Officer

Rule 10b5-1 trading arrangement

December 24, 2024

March 24, 2024 - December 31, 2025

513,000

Sales of shares intended to satisfy the affirmative defense of Rule 10b5–1(c)
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Rachel Humphrey  
Trading Arrangements, by Individual  
Name Rachel Humphrey
Title M.D.Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 5, 2024
Arrangement Duration 339 days
Aggregate Available 259,454
Lara Sullivan  
Trading Arrangements, by Individual  
Name Lara Sullivan
Title M.D.President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 24, 2024
Arrangement Duration 648 days
Aggregate Available 513,000